Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration

References

1. 1.↵
   1. Balzer T

   . Presence of Gadolinium (Gd) in the Brain and Body: Presentation to the Medical Imaging Drugs Advisory Committee, September 8, 2017. FDA. Silver Spring, Md: U.S. Food and Drug Administration. https://www.fda.gov/media/107670/download. Accessed February 5, 2020
2. 2.↵
   1. McDonald RJ,
   2. Levine D,
   3. Weinreb J, et al

   . Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018;289:517–34 doi:10.1148/radiol.2018181151 pmid:30204075

   CrossRefPubMed
3. 3.↵
   1. Boyd AS,
   2. Zic JA,
   3. Abraham JL

   . Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27–30 doi:10.1016/j.jaad.2006.10.048 pmid:17109993

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Grobner T

   . Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–08 doi:10.1093/ndt/gfk062 pmid:16431890

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Birka M,
   2. Wentker KS,
   3. Lusmoller E, et al

   . Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 2015;87:3321–28 doi:10.1021/ac504488k pmid:25708271

   CrossRefPubMed
6. 6.↵
   1. High WA,
   2. Ayers RA,
   3. Chandler J, et al

   . Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21–26 doi:10.1016/j.jaad.2006.10.047 pmid:17097388

   CrossRefPubMedWeb of Science
7. 7.↵
   1. High WA,
   2. Ayers RA,
   3. Cowper SE

   . Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710–12 doi:10.1016/j.jaad.2007.01.022 pmid:17289213

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Grobner T,
   2. Prischl FC

   . Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260–64 doi:10.1038/sj.ki.5002338 pmid:17507905

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Kanda T,
   2. Ishii K,
   3. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
10. 10.↵
    1. Kanda T,
    2. Osawa M,
    3. Oba H, et al

    . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

    CrossRefPubMed
11. 11.
    1. Boyken J,
    2. Frenzel T,
    3. Lohrke J, et al

    . Gadolinium accumulation in the deep cerebellar nuclei and globus pallidus after exposure to linear but not macrocyclic gadolinium-based contrast agents in a retrospective pig study with high similarity to clinical conditions. Invest Radiol 2018;53:278–85 doi:10.1097/RLI.0000000000000440 pmid:29319556

    CrossRefPubMed
12. 12.
    1. Jost G,
    2. Lenhard DC,
    3. Sieber MA, et al

    . Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Invest Radiol 2016;51:83–89 doi:10.1097/RLI.0000000000000242 pmid:26606548

    CrossRefPubMed
13. 13.
    1. Lohrke J,
    2. Frisk AL,
    3. Frenzel T, et al

    . Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2017;52:324–33 doi:10.1097/RLI.0000000000000344 pmid:28323657

    CrossRefPubMed
14. 14.
    1. Kartamihardja AA,
    2. Nakajima T,
    3. Kameo S, et al

    . Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium-based contrast agents in a mouse model. Br J Radiol 2016;89:20160509 doi:10.1259/bjr.20160509 pmid:27459250

    CrossRefPubMed
15. 15.
    1. McDonald RJ,
    2. McDonald JS,
    3. Dai D, et al

    . Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology 2017;285:536–45 doi:10.1148/radiol.2017161594 pmid:28640692

    CrossRefPubMed
16. 16.
    1. Moser FG,
    2. Watterson CT,
    3. Weiss S, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: comparison between gadobutrol and linear gadolinium-based contrast agents. AJNR Am J Neuroradiol 2018;39:421–26 doi:10.3174/ajnr.A5538 pmid:29419400

    Abstract/FREE Full Text
17. 17.
    1. Radbruch A,
    2. Weberling LD,
    3. Kieslich PJ, et al

    . Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2016;51:683–90 doi:10.1097/RLI.0000000000000308 pmid:27495187

    CrossRefPubMed
18. 18.
    1. Rasschaert M,
    2. Emerit A,
    3. Fretellier N, et al

    . Gadolinium retention, brain T1 hyperintensity, and endogenous metals: a comparative study of macrocyclic versus linear gadolinium chelates in renally sensitized rats. Invest Radiol 2018;53:328–37 doi:10.1097/RLI.0000000000000447 pmid:29329151

    CrossRefPubMed
19. 19.
    1. Robert P,
    2. Lehericy S,
    3. Grand S, et al

    . T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015;50:473–80 doi:10.1097/RLI.0000000000000181 pmid:26107651

    CrossRefPubMed
20. 20.
    1. Runge VM

    . Macrocyclic versus linear gadolinium chelates. Invest Radiol 2015;50:811 doi:10.1097/RLI.0000000000000229 pmid:26523911

    CrossRefPubMed
21. 21.
    1. Runge VM

    . Commentary on T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol 2015;50:481–82 doi:10.1097/RLI.0000000000000182 pmid:26107652

    CrossRefPubMed
22. 22.↵
    1. Schmitt-Willich H

    . Stability of linear and macrocyclic gadolinium-based contrast agents. Br J Radiol 2007;80:581–82 doi:10.1259/bjr/17326033 pmid:17704318

    FREE Full Text
23. 23.↵
    1. Edwards BJ,
    2. Laumann AE,
    3. Nardone B, et al

    . Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis: a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 2014;87:20140307 doi:10.1259/bjr.20140307 pmid:25230161

    CrossRefPubMed
24. 24.↵
    1. Lohani S,
    2. Golenbiewski J,
    3. Swami A, et al

    . A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. BMJ Case Rep 2017;2017 doi:10.1136/bcr-2017-221016 pmid:29025775

    Abstract/FREE Full Text
25. 25.↵
    FDA. Meeting Materials Cardiovascular and Renal Drugs Advisory Committee. March 19, 2009. Adelphi, Maryland. https://www.federalregister.gov/documents/2009/02/13/E9-3089/cardiovascular-and-renal-drugs-advisory-committee-notice-of-meeting. Accessed February 5, 2020
26. 26.↵
    1. Lima XT,
    2. Alora-Palli MB,
    3. Kimball AB, et al

    . Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken) 2013;65:637–42 doi:10.1002/acr.21877 pmid:23097320

    CrossRefPubMed
27. 27.↵
    1. Bryant BJ,
    2. Im K,
    3. Broome DR

    . Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol 2009;64:706–13 doi:10.1016/j.crad.2009.04.004 pmid:19520215

    CrossRefPubMed
28. 28.↵
    1. Nandwana SB,
    2. Moreno CC,
    3. Osipow MT, et al

    . Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 2015;276:741–47 doi:10.1148/radiol.2015142423 pmid:25875973

    CrossRefPubMed
29. 29.↵
    1. Soulez G,
    2. Bloomgarden DC,
    3. Rofsky NM, et al

    . Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3–5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol 2015;205:469–78 doi:10.2214/AJR.14.14268 pmid:26295633

    CrossRefPubMed
30. 30.↵
    1. Bruce R,
    2. Wentland AL,
    3. Haemel AK, et al

    . Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiol 2016;51:701–05 doi:10.1097/RLI.0000000000000259 pmid:26885631

    CrossRefPubMed
31. 31.↵
    1. Roberts DR,
    2. Chatterjee AR

    . The critical need for pediatric and juvenile animal research addressing gadolinium retention in the developing body. Invest Radiol 2019;54:72–75 doi:10.1097/RLI.0000000000000516 pmid:30273280

    CrossRefPubMed
32. 32.↵
    1. Vaneckova M,
    2. Herman M,
    3. Smith MP, et al

    . The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (the BENEFIT Study). AJNR Am J Neuroradiol 2015;36:1589–98 doi:10.3174/ajnr.A4468 pmid:26185325

    Abstract/FREE Full Text
33. 33.↵
    1. Khouri Chalouhi K,
    2. Papini GD,
    3. Bandirali M, et al

    . Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI. Eur J Radiol 2014;83:1245–49 doi:10.1016/j.ejrad.2014.03.030 pmid:24816087

    CrossRefPubMed
34. 34.↵
    1. Roberts DR,
    2. Lindhorst SM,
    3. Welsh CT, et al

    . High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol 2016;51:280–89 doi:10.1097/RLI.0000000000000266 pmid:26953564

    CrossRefPubMed
35. 35.
    1. Khurana A,
    2. Greene JF Jr.,
    3. High WA

    . Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218–24 doi:10.1016/j.jaad.2008.04.010 pmid:18538448

    CrossRefPubMedWeb of Science
36. 36.
    1. Christensen KN,
    2. Lee CU,
    3. Hanley MM, et al

    . Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2011;64:91–96 doi:10.1016/j.jaad.2009.12.044 pmid:21036418

    CrossRefPubMed